166 related articles for article (PubMed ID: 38932203)
1. The Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and Prevention.
Thavarajah JJ; Hønge BL; Wejse CM
Viruses; 2024 Jun; 16(6):. PubMed ID: 38932203
[TBL] [Abstract][Full Text] [Related]
2. Broadly Neutralizing Antibodies for HIV-1 Prevention.
Walsh SR; Seaman MS
Front Immunol; 2021; 12():712122. PubMed ID: 34354713
[TBL] [Abstract][Full Text] [Related]
3. Broadly neutralizing antibodies for HIV prevention: a comprehensive review and future perspectives.
Mahomed S
Clin Microbiol Rev; 2024 Jun; 37(2):e0015222. PubMed ID: 38687039
[TBL] [Abstract][Full Text] [Related]
4. A Rare Mutation in an Infant-Derived HIV-1 Envelope Glycoprotein Alters Interprotomer Stability and Susceptibility to Broadly Neutralizing Antibodies Targeting the Trimer Apex.
Mishra N; Sharma S; Dobhal A; Kumar S; Chawla H; Singh R; Das BK; Kabra SK; Lodha R; Luthra K
J Virol; 2020 Sep; 94(19):. PubMed ID: 32669335
[TBL] [Abstract][Full Text] [Related]
5. Adeno-associated virus gene delivery of broadly neutralizing antibodies as prevention and therapy against HIV-1.
Lin A; Balazs AB
Retrovirology; 2018 Oct; 15(1):66. PubMed ID: 30285769
[TBL] [Abstract][Full Text] [Related]
6. Neutralizing antibodies for HIV-1 prevention.
Julg B; Barouch DH
Curr Opin HIV AIDS; 2019 Jul; 14(4):318-324. PubMed ID: 31082819
[TBL] [Abstract][Full Text] [Related]
7. Adeno-Associated Viral Vector Mediated Expression of Broadly- Neutralizing Antibodies Against HIV-Hitting a Fast-Moving Target.
Sherpa C; Le Grice SFJ
Curr HIV Res; 2020; 18(2):114-131. PubMed ID: 32039686
[TBL] [Abstract][Full Text] [Related]
8. Broadly neutralizing antibodies targeting HIV: Progress and challenges.
Paneerselvam N; Khan A; Lawson BR
Clin Immunol; 2023 Dec; 257():109809. PubMed ID: 37852345
[TBL] [Abstract][Full Text] [Related]
9. Broadly neutralizing antibodies for the treatment and prevention of HIV infection.
Caskey M
Curr Opin HIV AIDS; 2020 Jan; 15(1):49-55. PubMed ID: 31764199
[TBL] [Abstract][Full Text] [Related]
10. Emergence of broadly neutralizing antibodies and viral coevolution in two subjects during the early stages of infection with human immunodeficiency virus type 1.
Sather DN; Carbonetti S; Malherbe DC; Pissani F; Stuart AB; Hessell AJ; Gray MD; Mikell I; Kalams SA; Haigwood NL; Stamatatos L
J Virol; 2014 Nov; 88(22):12968-81. PubMed ID: 25122781
[TBL] [Abstract][Full Text] [Related]
11. Cooperation between Strain-Specific and Broadly Neutralizing Responses Limited Viral Escape and Prolonged the Exposure of the Broadly Neutralizing Epitope.
Anthony C; York T; Bekker V; Matten D; Selhorst P; Ferreria RC; Garrett NJ; Karim SSA; Morris L; Wood NT; Moore PL; Williamson C
J Virol; 2017 Sep; 91(18):. PubMed ID: 28679760
[TBL] [Abstract][Full Text] [Related]
12. Broadly neutralizing antibodies against HIV-1 and concepts for application.
Gruell H; Schommers P
Curr Opin Virol; 2022 Jun; 54():101211. PubMed ID: 35306354
[TBL] [Abstract][Full Text] [Related]
13. Single-Chain Variable Fragments of Broadly Neutralizing Antibodies Prevent HIV Cell-Cell Transmission.
van Dorsten RT; Reh L; Trkola A; Morris L; Moore PL
J Virol; 2022 Feb; 96(4):e0193421. PubMed ID: 34935437
[TBL] [Abstract][Full Text] [Related]
14. Can Broadly Neutralizing HIV-1 Antibodies Help Achieve an ART-Free Remission?
Hsu DC; Mellors JW; Vasan S
Front Immunol; 2021; 12():710044. PubMed ID: 34322136
[TBL] [Abstract][Full Text] [Related]
15. Employing Broadly Neutralizing Antibodies as a Human Immunodeficiency Virus Prophylactic & Therapeutic Application.
Ding C; Patel D; Ma Y; Mann JFS; Wu J; Gao Y
Front Immunol; 2021; 12():697683. PubMed ID: 34354709
[TBL] [Abstract][Full Text] [Related]
16. Clinical Trials of Broadly Neutralizing Monoclonal Antibodies for Human Immunodeficiency Virus Prevention: A Review.
Mahomed S; Garrett N; Baxter C; Abdool Karim Q; Abdool Karim SS
J Infect Dis; 2021 Feb; 223(3):370-380. PubMed ID: 32604408
[TBL] [Abstract][Full Text] [Related]
17. Antiviral Therapy by HIV-1 Broadly Neutralizing and Inhibitory Antibodies.
Zhang Z; Li S; Gu Y; Xia N
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27869733
[TBL] [Abstract][Full Text] [Related]
18. Characterizing the Relationship Between Neutralization Sensitivity and
Wilson A; Shakhtour L; Ward A; Ren Y; Recarey M; Stevenson E; Korom M; Kovacs C; Benko E; Jones RB; Lynch RM
Front Immunol; 2021; 12():710327. PubMed ID: 34603284
[TBL] [Abstract][Full Text] [Related]
19. Broadly Neutralizing Antibodies for HIV Prevention.
Karuna ST; Corey L
Annu Rev Med; 2020 Jan; 71():329-346. PubMed ID: 31986089
[TBL] [Abstract][Full Text] [Related]
20. Positive Selection at Key Residues in the HIV Envelope Distinguishes Broad and Strain-Specific Plasma Neutralizing Antibodies.
Mabvakure BM; Scheepers C; Garrett N; Abdool Karim S; Williamson C; Morris L; Moore PL
J Virol; 2019 Mar; 93(6):. PubMed ID: 30567996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
